| Literature DB >> 22374313 |
Nura Suleiman Gwaram1, Hapipah Mohd Ali, Mahmood Ameen Abdulla, Michael J C Buckle, Sri Devi Sukumaran, Lip Yong Chung, Rozana Othman, Abeer A Alhadi, Wageeh A Yehye, A Hamid A Hadi, Pouya Hassandarvish, Hamid Khaledi, Siddig Ibrahim Abdelwahab.
Abstract
Alzheimer's disease (AD) is the most common form of dementia among older people and the pathogenesis of this disease is associated with oxidative stress. Acetylcholinesterase inhibitors with antioxidant activities are considered potential treatments for AD. Some novel ketone derivatives of gallic hydrazide-derived Schiff bases were synthesized and examined for their antioxidant activities and in vitro and in silico acetyl cholinesterase inhibition. The compounds were characterized using spectroscopy and X-ray crystallography. The ferric reducing antioxidant power (FRAP) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays revealed that all the compounds have strong antioxidant activities. N-(1-(5-bromo-2-hydroxyphenyl)-ethylidene)-3,4,5-trihydroxybenzohydrazide (2) was the most potent inhibitor of human acetyl cholinesterase, giving an inhibition rate of 77% at 100 μM. Molecular docking simulation of the ligand-enzyme complex suggested that the ligand may be positioned in the enzyme's active-site gorge, interacting with residues in the peripheral anionic subsite (PAS) and acyl binding pocket (ABP). The current work warrants further preclinical studies to assess the potential for these novel compounds for the treatment of AD.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22374313 PMCID: PMC6268099 DOI: 10.3390/molecules17032408
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Reaction pathways.
Figure 1ORTEP-type view of the crystal structure of compound 4 showing the labeling scheme. Thermal ellipsoids are drawn at the 50% probability level.
Selected bond distances (Å) and angles (°) for compound 4.
| Distances | |
|---|---|
| N1-N2 | 1.375(4) |
| N1-C8 | 1.294(4) |
| N2-C10 | 1.374(4) |
| C10-O3 | 1.231(4) |
|
| |
| C8-N1-N2 | 121.0(3) |
| C10-N2-N1 | 116.6(3) |
| O3-C10-N2 | 120.5(3) |
| O2-C5-C6 | 123.0(3) |
Crystal data and structure refinement for 4 and 5.
| Identification code | 4 | 5 |
|---|---|---|
| Empirical formula | C16H18N2O7 | C14H12N3O5 |
| Formula weight | 350.32 | 302.27 |
| Temperature/K | 569(2) | 296 |
| Crystal system | Monoclinic | triclinic |
| Space group | P21/n | P-1 |
| a/Å | 7.769(9) | 6.6282(7) |
| b/Å | 15.509(19) | 9.9326(7) |
| c/Å | 13.162(16) | 12.8906(11) |
| α/° | 90 | 79.982(2) |
| β/° | 103.85(2) | 80.995(2) |
| γ/° | 90 | 76.5060(10) |
| Volume/Å3 | 1,540(3) | 806.67(12) |
| Z | 4 | 2 |
| ρcalcmg/mm3 | 1.511 | 1.244 |
| m/mm‑1 | 0.12 | 0.097 |
| F(000) | 736 | 314 |
| Crystal size/mm3 | 0.28 × 0.05 × 0.01 | 0.33 × 0.14 × 0.11 |
| 2Θ range for data collection | 4.14 to 50° | 3.24 to 61.08° |
| Index ranges | −5 ≤ h ≤ 9, −18 ≤ k ≤ 18, −15 ≤ l ≤ 14 | −8 ≤ h ≤ 6, −14 ≤ k ≤ 10, −17 ≤ l ≤ 17 |
| Reflections collected | 7,052 | 2,552 |
| Independent reflections | 2,704[R(int) = 0.0721] | 2,237[R(int) = 0.0358] |
| Data/restraints/parameters | 2,704/3/241 | 2,237/12/254 |
| Goodness-of-fit on F2 | 0.986 | 0.804 |
| Final R indexes [I >= 2σ (I)] | R1 = 0.0532, wR2 = 0.1121 | R1 = 0.0462, wR2 = 0.1239 |
| Final R indexes [all data] | R1 = 0.1117, wR2 = 0.1358 | R1 = 0.0555, wR2 = 0.1354 |
| Largest diff. peak/hole/e Å−3 | 0.305/−0.264 | 0.43/−0.34 |
Human AChE inhibitory effects and anti-oxidant activities for compounds 1–6.
| Compounds | Molecular weight | AChE Inhibition (%)(Final conc. = 1 × 10−4 M) | DPPH(IC50, μg/mL) | FRAP value(Mean ± SD) |
|---|---|---|---|---|
| 184.15 | 38.0 ± 1.3 | 1.210 ± 0.002 | 81,633.30 ± 0.075 | |
| 381.18 | 77.0 ± 1.8 | 1.140 ± 0.001 | 62,200.00 ± 0.083 | |
| 336.73 | 68.9 ± 1.8 | 1.400 ± 0.002 | 35,740.00 ± 0.011 | |
| 332.31 | 48.5 ± 2.5 | 1.220 ± 0.001 | 30,080.00 ± 0.054 | |
| 287.27 | 16.4 ± 1.4 | 1.460 ± 0.001 | 22,946.70 ± 0.004 | |
| 329.31 | 71.5 ± 1.7 | 2.300 ± 0.001 | 23,340.00 ± 0.021 | |
| Propidium | - | 54.5 ± 1.6 | - | - |
| Tacrine | - | 51.2 ± 1.6 | - | - |
| Ascorbic acid | - | - | 2.260 ± 0.001 | 19,400.00 ± 0.007 |
| BHT | - | - | - | 187.3 ± 2.6 |
1: Gallic hydrazide; 2: N-(1-(5-Bromo-2-hydroxyphenyl)-ethylidene)-3,4,5-trihydroxybenzohydrazide; 3: N-(1-(5-Chloro-2-hydroxyphenyl)-ethylidene)-3,4,5-trihydroxybenzohydrazide; 4: N-(1-(2-Hydroxy-5-methoxyphenyl)-ethylidene)-3,4,5-trihydroxybenzohydrazide; 5: 3,4,5-Trihydroxybenzoic acid [1-pyridylethylidene] hydrazide, 6: 3,4,5-Trihydroxybenzoic acid [1-(4-acetyl-pyridin-2-yl)-ethylidene] hydrazide; BHT: Butylated hydroxytoluene.
Figure 2Representations of the molecular model of the complex formed between compound 2 and hAChE. (a) 3D representation of the ligand-enzyme binding interactions. Compound 2 is represented as a dark grey sticks and hydrogen bonds as green dashed lines; (b) 2D schematic representation of the hydrogen bonding and hydrophobic interactions.
Figure 3Representations of the molecular model of the complex formed between compound 3 and hAChE. (a) 3D representation of the ligand-enzyme binding interactions. Compound 3 is represented as a dark grey sticks and hydrogen bonds as green dashed lines; (b) 2D schematic representation of the hydrogen bonding and hydrophobic interactions.
Figure 4Representations of the molecular model of the complex formed between compound 6 and hAChE. (a) 3D representation of the ligand-enzyme binding interactions. Compound 6 is represented as a dark grey sticks and hydrogen bonds as green dashed lines; (b) 2D schematic representation of the hydrogen bonding and hydrophobic interactions.